Vaccine expert: The U.S. doesn't need to rely on J&J vaccine

Anjalee Khemlani

The U.S. is unlikely to be significantly affected in its vaccination efforts after use of Johnson & Johnson's (JNJ) vaccine was halted by the U.S. Food and Drug Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) Tuesday due to concerns of a rare side effect.

The FDA and CDC said in a joint statement that out of more than 6.8 million doses administered of the J&J vaccine, there were six reports, including one fatality, of a rare blood clot in the brain — known as cerebral venous sinus thrombosis.

"All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination," according to the statement.

"We are recommending a pause in the use of this vaccine out of an abundance of caution," the two health agencies added.

Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at FDA, said the fact sheet provided to health professionals will be updated to include the information about the blood clots.

Marks and FDA interim director Dr. Janet Woodcock said during a media briefing that the occurrence remains very rare, and a probable cause is yet unknown.

"This is an immune response that occurs very, very rarely after some people receive the vaccine," Marks said.

Woodcock noted the information is "going to be very concerning to Americans" but the agencies will be providing an update in the coming days.

For now, anyone who received the vaccine over a month ago is at low risk, and anyone who received it in recent weeks should remain alert for any symptoms, including severe headaches, abdominal pain, leg pain or shortness of breath.

Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and one of the independent experts on the FDA's vaccine advisory committee, told Yahoo Finance the move by the health agencies to recommend the vaccine's halt is not unexpected after similar reports with AstraZeneca's (AZN) vaccine in Europe.

"Now we're finding, it is a class effect" among the viral vector vaccine platforms, Offit said.

He added that the J&J pause is unlikely to affect the U.S. rollout as both mRNA vaccines comprise a vast majority of the committed doses the country has purchase — 300 million in total from both Moderna (MRNA) and Pfizer (PFE)/ BioNTech (BNTX).

"I don't think we necessarily need to rely on the Johnson & Johnson vaccine," Offit said, adding that between the mRNA options, "We are going to be able to vaccinate all Americans by mid-summer."

It is unclear as of Tuesday if, as in in some European countries, younger women will be excluded among the recommended recipients of the J&J vaccine.

The concerns have prompted questions about other COVID-19 vaccines. In a statement Tuesday, Moderna proactively addressed the issue, noting that there has been no link between the specific blood clots — occurring in the brain— and its vaccine.

In a statement Tuesday, J&J said it was proactively delaying its vaccine rollout in Europe.

"We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine," the company said, adding, "We have been reviewing these cases with European health authorities."

The CDC will convene its vaccine advisory committee Wednesday to review the cases and "assess their potential significance."

The FDA will further review the reports as well, recommending a pause in the use of the vaccine until the process concludes.

More from Anjalee:

Read the latest financial and business news from Yahoo Finance.

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, LinkedIn, YouTube.

Follow Anjalee on Twitter @AnjKhem.

Advertisement